ELTX

Elicio Therapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer treatment. The company's proprietary Amphiphile (AMP) platform technology is designed to direct immune responses to lymph nodes, where T cells are activated. Elicio's lead programs focus on cancer vaccines and immunomodulatory therapies that aim to generate robust and durable anti-tumor immune responses. The company is conducting clinical trials in multiple cancer types, including pancreatic cancer and other solid tumors with significant unmet medical needs.